Jana Care, Inc. an early stage at-home In Vitro Diagnostics company, and Roche Diagnostics announced a collaboration agreement for its digitally connected, blood testing platform to enable patients to self-administer critical blood tests at-home and clinicians to review the test results remotely. Initially focused on monitoring the progression of chronic kidney disease and heart failure, the platform is designed to overcome distance and socioeconomic hurdles impeding adequate and timely detection and monitoring of disease progression and risk management. "The addition of a world-class strategic partner such as Roche to our existing development relationships provides strong support to the company’s momentum in bringing this groundbreaking technology to market," said Anh Hoang-Lindsay, Chief Executive Officer of Jana Care. "The need for improving real point-of-care testing is critical as innovation needs to keep pace with our more decentralized healthcare model."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on RHHBY:
- Vaccitech appoints Pelletier as Chief Scientific Officer
- Spark Therapeutics enters collaboration with Neurochase
- Roche launches COVID-19 PCR test to detect XBB.1.5 Omicron sub-variant
- Roche launches COVID-19 PCR test to detect the fast spreading XBB.1.5 Omicron sub-variant
- TG Therapeutics price target raised to $25 from $16 at Evercore ISI
